FIELD: medicine.
SUBSTANCE: disclosed is a method of treating Sjogren's syndrome (SjS) in a subject in need thereof, comprising administering a daily dose of about 10 mg to approximately 200 mg of a compound of formula (I)
(I)
or a pharmaceutically acceptable salt thereof, where the term approximately indicates a deviation of ±10%.
EFFECT: invention provides treating Sjogren's syndrome with a compound of formula (I) in effective and safe doses.
16 cl, 7 dwg, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CHRONIC SPONTANEOUS URTICARIA USING BRUTON TYROSINE KINASE INHIBITOR | 2020 |
|
RU2818678C2 |
| LTA4H INHIBITORS FOR TREATING PURULENT HYDRADENITIS | 2020 |
|
RU2821362C2 |
| COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF VASOMOTOR SYMPTOMS | 2018 |
|
RU2815402C2 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
| METHODS OF TREATING DISEASES ASSOCIATED WITH S1P1 RECEPTOR | 2021 |
|
RU2821032C1 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND APPLICATIONS THEREOF | 2017 |
|
RU2766155C2 |
| TYROSINE KINASE INHIBITOR OR ITS PHARMACEUTICAL SALT FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS | 2016 |
|
RU2778337C2 |
| COMBINATION OF PI3 KINASE INHIBITOR WITH PACLITAXEL FOR USE IN TREATMENT OR PREVENTION OF HEAD AND NECK CANCER | 2014 |
|
RU2672555C2 |
| USE OF A DERIVATIVE GLUTARIMIDE TO OVERCOME RESISTANCE TO STEROIDS AND THERAPY OF DISEASES ASSOCIATED WITH ABERRANT SIGNALING OF INTERFERON GAMMA | 2018 |
|
RU2712281C1 |
| CD40L ANTAGONIST AND METHODS OF ITS USE | 2019 |
|
RU2812919C2 |
